Jasper Therapeutics
JSPR
61 hedge funds and large institutions have $380M invested in Jasper Therapeutics in 2024 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 20 increasing their positions, 8 reducing their positions, and 13 closing their positions.
399% more call options, than puts
Call options by funds: $4.27M | Put options by funds: $855K
316% more capital invested
Capital invested by funds: $91.4M → $380M (+$289M)
154% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 13
150% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 8
100% more funds holding in top 10
Funds holding in top 10: 3 → 6 (+3)
79.6% more ownership
Funds ownership: 6.92% → 86.51% (+80%)
49% more funds holding
Funds holding: 41 → 61 (+20)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$13.5M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$12.8M |
| 3 |
SB
Samsara BioCapital
Palo Alto,
California
|
+$9.33M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$7.71M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$7.24M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$2.9M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$1.76M |
| 3 |
ABG
Ally Bridge Group
New York
|
-$1.35M |
| 4 |
LCM
Landscape Capital Management
Englewood,
New Jersey
|
-$1.2M |
| 5 |
SVCM
Saturn V Capital Management
Austin,
Texas
|
-$1.09M |
JSPR Hedge Fund Activity: Q1 2024 in Review
61 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Jasper Therapeutics (JSPR) for Q1 2024, worth a combined $380M — up 316% from $91.4M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new JSPR positions and 13 closed out — a net gain of 20 holders — while 20 added to existing stakes and 8 trimmed.
The largest buyer was Avidity Partners Management, opening a new position worth an estimated $13.5M. The largest seller was Morgan Stanley, cutting an estimated $2.9M.
- 61 institutional investors held Jasper Therapeutics (JSPR) as of Q1 2024, up from 41 in Q4 2023.
- Funds reported $380M of Jasper Therapeutics stock for Q1 2024, up 316% quarter-over-quarter.
- 33 funds opened new Jasper Therapeutics positions in Q1 2024 and 13 closed out, a net change of +20 holders.
- The largest Jasper Therapeutics buyer in Q1 2024 was Avidity Partners Management, an estimated $13.5M added.
- The largest Jasper Therapeutics seller in Q1 2024 was Morgan Stanley, an estimated $2.9M sold.
Based on aggregated 13F filings for Q1 2024.